{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:51:06Z","timestamp":1787028666175,"version":"build-2736575974"},"reference-count":57,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Continuity of care for rheumatoid arthritis patients within regional networks enables stable long-term clinical data collection, despite chronic rheumatologist shortages in Japan. We determined 5-year drug survival and discontinuation reasons for eight biological disease-modifying antirheumatic drugs (bDMARDs) using a regional multicenter registry. Methods: We retrospectively analyzed 1182 patients initiating their first (na\u00efve, n = 784) or subsequent (switch, n = 398) bDMARD between May 2001 and August 2022 across five institutions. The primary endpoint (5-year drug survival) and secondary endpoints (discontinuation risk factors and cumulative incidence of reasons) were evaluated using Kaplan\u2013Meier curves, Cox proportional hazards, and Fine &amp; Gray models. Results: Baseline characteristics varied significantly among bDMARDs. Five-year drug survival in the na\u00efve cohort ranged from tocilizumab (50.8%) to golimumab (22.6%); in the switch cohort, from abatacept (42.6%) to infliximab (10.0%). In multivariable Cox analysis of na\u00efve patients, male sex (hazard ratio [HR] = 1.49, 95% confidence interval [CI] = 1.09\u20132.02), lower baseline 28-joint Disease Activity Score with erythrocyte sedimentation rate (DAS28-ESR) (HR = 0.90, 95% CI = 0.82\u20130.99), and absence of methotrexate co-therapy (HR = 0.73, 95% CI = 0.55\u20130.97) predicted discontinuation. The lower baseline DAS28-ESR association potentially reflects successful courses toward intentional cessation following remission. Discontinuations were attributed to inadequate response (27.1%), non-adverse events (25.3%), and adverse events (17.3%). Conclusions: Tocilizumab and abatacept demonstrated the highest retention rates in biologic-na\u00efve and switch cohorts, respectively. Early, individualized drug selection and dose optimization are crucial to maximizing long-term bDMARD effectiveness before switching.<\/jats:p>","DOI":"10.3390\/jcm15052075","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:06:52Z","timestamp":1773054412000},"page":"2075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Five-Year Drug Survival and Discontinuation Reasons for Eight Biological Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Retrospective Analysis of 1182 Patients from the Niigata Orthopedic Surgery Rheumatoid Arthritis Database (NOSRAD)"],"prefix":"10.3390","volume":"15","author":[{"given":"Nariaki","family":"Hao","sequence":"first","affiliation":[{"name":"Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-3055","authenticated-orcid":false,"given":"Naoki","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumitsu","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Niigata Prefectural Central Hospital, 205 Shinnan-cho, Joetsu-shi, Niigata 943-0192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kudo","sequence":"additional","affiliation":[{"name":"Katsumi Seikeigeka Clinic, 1-27-12 Toyano, Chuo-ku, Niigata 950-0951, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Murai","sequence":"additional","affiliation":[{"name":"Murai Seikeigeka Clinic, 1-3-6 Kamikido, Higashi-ku, Niigata 950-0891, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, NHO Nishiniigata Chuo Hospital, 1-14-1 Masago, Nishi-ku, Niigata 950-2085, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Kijima","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Kakutani","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-9773","authenticated-orcid":false,"given":"Hiroyuki","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.18632\/oncotarget.13953","article-title":"Early detection of rheumatoid arthritis in rats and humans with 99mTc-3PRGD2 scintigraphy: Imaging synovial neoangiogenesis","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.berh.2010.10.001","article-title":"Rheumatoid arthritis","volume":"24","author":"Carmona","year":"2010","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kondo, N., Kuroda, T., and Kobayashi, D. (2021). Cytokine networks in the pathogenesis of rheumatoid arthritis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222010922"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/14397595.2013.854069","article-title":"Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: Results from 3 years of prospectively registered data","volume":"24","author":"Nakashima","year":"2014","journal-title":"Mod. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/14397595.2016.1170958","article-title":"Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses","volume":"27","author":"Nakashima","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the Stream study): Evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ebina, K., Hashimoto, M., Yamamoto, W., Ohnishi, A., Kabata, D., Hirano, T., Hara, R., Katayama, M., Yoshida, S., and Nagai, K. (2018). Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -the ANSWER cohort study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194130"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00508-018-1321-4","article-title":"Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011: A retrospective analysis of 72% of the population","volume":"130","author":"Stamm","year":"2018","journal-title":"Wien Klin. Wochenschr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/14397595.2018.1537556","article-title":"Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: A 14 year-retrospective study from a rheumatology clinic in Japan","volume":"29","author":"Kondo","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1265\/ehpm.22-00169","article-title":"Factors related to Japanese internal medicine doctors\u2019 retention or migration to rural areas: A nationwide retrospective cohort study","volume":"28","author":"Saijo","year":"2023","journal-title":"Environ. Health Prev. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/mr\/roaf068","article-title":"The need for telemedicine for rheumatic diseases in adult medical care: A Survey of non-pediatric rheumatologists","volume":"36","author":"Iwata","year":"2025","journal-title":"Mod. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Moldovan, F., and Moldovan, L. (2024). Evaluation of Community Involvement and Development in an Orthopedic Hospital. Healthcare, 12.","DOI":"10.3390\/healthcare12131286"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use soft- ware \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-019-1880-4","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study","volume":"21","author":"Ebina","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14397595.2018.1447264","article-title":"Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data","volume":"29","author":"Takabayashi","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13075-020-02233-9","article-title":"Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry","volume":"22","author":"Kawabe","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: Prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.31138\/mjr.090723.pof","article-title":"Predictors of drug retention and survival rate of bDMARDs in rheumatoid arthritis: A four-year real-life Tunisian experience","volume":"35","author":"Boussaid","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/03009742.2012.762037","article-title":"Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis","volume":"42","author":"Hishitani","year":"2013","journal-title":"Scand. J. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: A systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_26","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: A systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Dehler","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lin, C.T., Huang, W.N., Tsai, W.C., Chen, J.P., Hung, W.T., Hsieh, T.Y., Chen, H.H., Hsieh, C.W., Lai, K.L., and Tang, K.T. (2021). Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0250877"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","article-title":"Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: Systematic review and meta-analysis","volume":"173","author":"Maneiro","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203893","article-title":"Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis","volume":"74","author":"Chen","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/kex474","article-title":"Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: The REASON study","volume":"57","author":"Balsa","year":"2018","journal-title":"Rheumatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1186\/ar4315","article-title":"Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): An observational study","volume":"15","author":"Hirata","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e000189","DOI":"10.1136\/rmdopen-2015-000189","article-title":"Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study","volume":"2","author":"Tanaka","year":"2016","journal-title":"RMD Open"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/annrheumdis-2016-210246","article-title":"Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial","volume":"76","author":"Atsumi","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/14397595.2015.1123349","article-title":"Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study","volume":"26","author":"Yamanaka","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: Real-life data from a local registry","volume":"68","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2011-200302","article-title":"Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: Data from the Spanish registry BIOBADASER 2.0","volume":"71","author":"Montoro","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","first-page":"431","article-title":"Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate","volume":"35","author":"Kneepkens","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/03009742.2025.2471713","article-title":"Sex differences in treatment response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitor: A cohort study from the DANBIO registry","volume":"54","author":"Lauridsen","year":"2025","journal-title":"Scand. J. Rheumatol."},{"key":"ref_43","first-page":"882","article-title":"Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy","volume":"27","author":"Peter","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Carmona, L., Aurrecoechea, E., and Garc\u00eda de Y\u00e9benes, M.J. (2023). Tailoring rheumatoid arthritis treatment through a sex and gender lens. J. Clin. Med., 13.","DOI":"10.20944\/preprints202311.1009.v1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e001203","DOI":"10.1136\/rmdopen-2020-001203","article-title":"Body mass index and treatment survival in patients with RA starting treatment with TNF\u03b1-inhibitors: Long-term follow-up in the real-life Meteor registry","volume":"6","author":"Bergstra","year":"2020","journal-title":"RMD Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13075-023-03187-4","article-title":"High BMI is associated with lower TNF-\u03b1 inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis","volume":"25","author":"Arends","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_47","unstructured":"World Health Organization (2023). WHO Report on the Global Tobacco Epidemic Country Profile: Japan, WHO."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40744-022-00464-7","article-title":"Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study","volume":"9","author":"Michelsen","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e000155","DOI":"10.1136\/rmdopen-2015-000155","article-title":"Discontinuation rates of biologics in patients with rheumatoid arthritis: Are TNF inhibitors different from non-TNF inhibitors?","volume":"1","author":"Ramiro","year":"2015","journal-title":"RMD Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","article-title":"Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: Data from the Swiss Clinical Quality Management Registry","volume":"54","author":"Gabay","year":"2015","journal-title":"Rheumatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e000363","DOI":"10.1136\/rmdopen-2016-000363","article-title":"Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: A 76-week prospective study","volume":"3","author":"Takahashi","year":"2017","journal-title":"RMD Open"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/annrheumdis-2019-216537","article-title":"Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy","volume":"79","author":"Jacobs","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: Data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40259-025-00716-2","article-title":"Frequency of Biological Drug Use in Older Patients with Immune-Mediated Inflammatory Diseases: Results from the Large-Scale Italian VALORE Distributed Database Network","volume":"39","author":"Soardo","year":"2025","journal-title":"BioDrugs"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: Recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/2075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:29:49Z","timestamp":1773055789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/2075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15052075"],"URL":"https:\/\/doi.org\/10.3390\/jcm15052075","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}